Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: April 2011

Chapter 37 - Antiepileptic and antipsychotic drugs

References

1. Kofke WA, Ahdab-Barmada M, Rose M, Clyde C, Nemoto E. Substantia nigra damage after flurothyl-induced seizures in rats worsens after post seizure recovery: no exacerbation with hyperglycemia. Neurol Res 1993; 15: 333.
2. Abramowicz E. Drugs for epilepsy. Treat Guidel Med Lett 2008; 6: 37–48.
3. Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther 2007; 113: 165–83.
4. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291: 605–14.
5. Gatti G, Bonomi I, Jannuzzi G, Perucca E. The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharm Des 2000; 6: 839–60.
6. Perucca E. Marketed new antiepileptic drugs: are they better than old-generation agents? Ther Drug Monit 2002; 24: 74–80.
7. Foldavary-Shaefer N, Wyllie E. Neuropharmacology of the antiepileptic drugs. In: C. Goetz, ed., Textbook of Clinical Neurology, 2nd edn. New York, NY: Elsevier, 2003.
8. Lacerda G, Krummel T, Sabourdy C, Ryvlin P, Hirsch E. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67: S28–33.
9. Bourgeois BF. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology 2000; 55: S11–16.
10. Baumgartner C, Stefan H. Epilepsien. In: Stefan H, Mamoli B, eds., Aktuelle Therapie in der Neurologie: Kompendium für die Fort-und Weiterbildung. Landsberg/Lech: Ecomed, 2006.
11. Michelucci R. Optimizing therapy of seizures in neurosurgery. Neurology 2006; 67: S14–18.
12. Ryvlin P, Montavont A, Nighoghossian N. Optimizing therapy of seizures in stroke patients. Neurology 2006; 67: S3–9.
13. Steinhoff BJ. Optimizing therapy of seizures in patients with endocrine disorders. Neurology 2006; 67: S23–7.
14. Mattson RH. Medical management of epilepsy in adults. Neurology 1998; 51: S15–20.
15. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252–60.
16. Pfizer. Dilantin capsule drug label, 2007. www.pfizer.com/files/products/uspi_dilantin.pdf (accessed March 26, 2010).
17. Walton NY, Jaing Q, Hyun B, Treiman DM. Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. Epilepsy Res 1996; 24: 19–28.
18. Löscher W, Reissmüller E, Ebert U. Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin. Epilepsy Res 1998; 30: 69–76.
19. Brückner C, Heinemann U. Effects of standard anticonvulsant drugs on different patterns of epileptiform discharges induced by 4-aminopyridine in combined entorhinal cortex-hippocampal slices. Brain Res 2000; 859: 15–20.
20. Zivanovic D, Stanojlovic O, Susic V, Stojanovic J. The effects of phenytoin and phenobarbital on seizures induced by imipenem/cilastatin in rats. Acta Neurol Belg 2004; 104: 20–6.
21. Bough KJ, Eagles DA. Comparison of the anticonvulsant efficacies and neurotoxic effects of valproic acid, phenytoin, and the ketogenic diet. Epilepsia 2001; 42: 1345–53.
22. Hashimoto Y, Araki H, Futagami K, Kawasaki H, Gomita Y. Effects of valproate, phenytoin, and zonisamide on clonic and tonic seizures induced by acute and repeated exposure of mice to flurothyl. Physiol Behav 2003; 78: 465–9.
23. Sinz EH, Kofke WA, Garman RH. Phenytoin, midazolam, and naloxone protect against fentanyl-induced brain damage in rats. Anesth Analg 2000; 91: 1443–9.
24. Rogers JF, Nafziger AN, Bertino JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 746–50.
25. Parke-Davis. Cerebyx drug label, 2003. www.pfizer.com/files/products/uspi_cerebyx.pdf (accessed March 24, 2010).
26. Manno EM. New management strategies in the treatment of status epilepticus. Mayo Clin Proc 2003; 78: 508–18.
27. Wagner JG. Time to reach steady state and prediction of steady-state concentrations for drugs obeying Michaelis-Menten elimination kinetics. J Pharmacokinet Biopharm 1978; 6: 209–25.
28. Browne TR. Pharmacokinetics of antiepileptic drugs. Neurology 1998; 51: S2–7.
29. Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996; 46: S3–7.
30. Epilepsy Foundation. Phenobarbital. www.epilepsyfoundation.org/answerplace/Medical/treatment/medications/typesmedicine/phenobarbital.cfm (accessed March 27, 2010).
31. RxList. Phenobarbital. www.rxlist.com/cgi/generic/phenbarb.htm (accessed March 27, 2010).
32. Britton JW, So EL. Selection of antiepileptic drugs: a practical approach. Mayo Clin Proc 1996; 71: 778–86.
33. Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet 2006; 367: 1087–100.
34. Czapiński P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005; 5: 3–14.
35. Macdonald RL. Anticonvulsant drug actions on neurons in cell culture. J Neural Transm 1988; 72: 173–83.
36. Valeant. Mysoline drug label, 2007. dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=5721 (accessed March 26, 2008).
37. Leppik IE. Monotherapy and polypharmacy. Neurology 2000; 55: S25–9.
38. Roche. Klonopin drug label. www.accessdata.fda.gov/drugsatfda_docs/label/2009/017533s045,020813s005lbl.pdf (accessed March 24, 2008).
39. Kofke WA, Towfighi J, Garman RH, et al. Effects of anesthetics on neuropathologic sequelae of status epilepticus in rats. Anesth Analg 1993; 77: 330–7.
40. George B, Kulkarni SK. Protective effects of GABAergic drugs and other anticonvulsants in lithium-pilocarpine-induced status epilepticus. Methods Find Exp Clin Pharmacol 1996; 18: 335–40.
41. Martín ED, Pozo MA. Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region. Epilepsia 2003; 44: 1375–9.
42. McNamara J. Pharmacotherapy of the epilepsies. In: Brunton LL, ed., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York, NY: McGraw Hill, 2006.
43. Parke-Davis. Zarontin drug label, 2003. www.fda.gov/cder/foi/label/2001/12380s25lbl.PDF (accessed March 24, 2008).
44. Gören MZ, Onat F. Ethosuximide: from bench to bedside. CNS Drug Rev 2007; 13: 224–39.
45. Novartis. Tegretol drug label, 2007. www.fda.gov/cder/foi/label/2007/016608s098lbl.pdf (accessed March 24, 2008).
46. Novartis. Trileptal drug label. www.pharma.us.novartis.com/product/pi/pdf/trileptal.pdf (accessed March 25, 2010).
47. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261–73.
48. Ortho-McNeil Neurologics. Topamax drug label, 2007. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4130 (accessed April 2, 2008).
49. Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ. The use of topiramate in refractory status epilepticus. Neurology 2003; 60: 332–4.
50. Vazquez B. Monotherapy in epilepsy: role of the newer antiepileptic drugs. Arch Neurol 2004; 61: 1361–5.
51. GlaxoSmithKline. Lamictal drug label, 2006. www.fda.gov/cder/foi/label/2006/020241SLRs10s21s 25s26s27,020764SLRs3s14s18s19s20lbl.pdf (accessed March 25, 2008).
52. Cephalon. Gabitril drug label, 2006. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=2617 (accessed April 2, 2008).
53. Willmore LJ. Clinical pharmacology of new antiepileptic drugs. Neurology 2000; 55: S17–24.
54. Elsai. Zonegran drug label, 2007. dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=4721 (accessed April 7, 2008).
55. Anonymous. Gabapentin FDA Approved Labeling Text, 2005. www.fda.gov/medwatch/SAFETY/2005/Feb_PI/Neurontin_PI.pdf (accessed March 23, 2008).
56. Pfizer. Lyrica drug label. 2007. dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=5166 (accessed March 27, 2008).
57. Medpointe. Felbatol drug label. www.felbatol.com/pi.pdf (accessed March 25, 2010).
58. UCB. Keppra drug label. 2007. www.fda.gov/cder/foi/label/2007/021035s057,021505s013lbl.pdf (accessed March 26, 2010).
59. Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, ed., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York, NY: McGraw Hill, 2006 [and accompanying online drug monographs].
60. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.
61. Wooten J. Metabolic effects of the atypical antipsychotics. South Med J 2007; 100: 771–2.
62. Baxter. Chlorpromazine drug label, 2006. dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=2277 (accessed April 16, 2008).
63. Sandoz. Perphenazine drug label, 2008. dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=6633 (accessed March 26, 2010).